We intend to continue our business development effort by adding other proven domestic and international biotechnology partners to monetize the China health care market
CBMG has its corporate headquarter offices and an R&D facility in Rockville, Maryland, USA. We also have affiliates across Asia, including Hong Kong, manufacturing facilities in Wuxi, China and an international-standard protocol-compliant R&D and manufacturing facility in Shanghai, China.
We are a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and autoimmune conditions.
CBMG’s primary target market is Greater China. We are also expanding into the global market by seeking international strategic collaborations in the U.S. and abroad.
CBMG operates on a fiscal year that runs from January 1 to December 31. Quarter-ends are: March 31 (Q1), June 30 (Q2), and September 30 (Q3).